When you have decided a biologic is the next step
Consider ENBREL for Patients with Psoriatic Arthritis

Psoriatic arthritis (PsA) is an inflammatory autoimmune disorder that affects the skin and both proximal and distal joints.1

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

In the PsA pivotal study, patients on ENBREL achieved significant clinical efficacy in PsA2:

Reduced clinical
signs and symptoms

See change from baseline in pain, morning stiffness, and CRP.

View Data

Improved
physical function

See reductions in HAQ score out to Year 2.

View Data

Inhibited progression of
joint damage

See changes in mTSS out to Year 2.

View Data

Improved
skin symptoms

See improvements in mean PASI score.

View Data

PsA can cause substantial impairment of physical function and may lead to progressive joint damage

Impairment of physical function1,3:

  • Physical function generally worsens as the number of inflamed joints and disease activity increase

Joint damage occurs progressively1,3,4:

  • Joint damage may progress despite improvements in symptoms3,4
  • The percentage of patients with joint erosions increased from 27% to 47% over 2 years in one study1
 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations
Play video

Phil Mickelson: A PsA Patient's Perspective

Listen to Phil share his personal experience to gain more insight about your patients.

Play video

Introducing ENBREL Nurse Partners

Dedicated registered nurses are now available to give your patients the personal assistance
they need.

Here's how they can help
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years